Flowchem Strengthens Leadership Team, Appointing COO, Technology Team, and Board of Senior Industry Experts
13.2.2025 13:00:00 CET | Business Wire | Press release
Flowchem (“Flowchem” or the “Company”) and SCFPartners (“SCF”) are pleased to announce several personnel additions. Flowchem is a leading global player in the drag reducing agent (“DRA”) market, providing custom-engineered specialty chemicals to help customers around the world optimize the performance of their infrastructure. These key appointments bolster the already-strong management team in place at the time of the Company’s acquisition in 2024, positioning it for continued growth and industry leadership.
- Shivali Agarwal has been appointed as Chief Operating Officer (“COO”). Shivali brings decades of industry operating experience in roles across the globe, most recently serving as Group General Manager, Production Systems at SLB (NYSE:SLB). Shivali holds a Master of Business Administration from Harvard Business School and a Master of Science in Biological Sciences and a Bachelor of Science in Chemical Engineering from the Birla Institute of Technology & Science, Pilani, India.
-
Flowchem has bolstered its technology team with several key technical hires, significantly enhancing its product development capabilities. Dr. Lu-Chien Chou is a recognized leader in the field who has led cutting-edge DRA research at Baker Hughes (NASDAQ:BKR) and other DRA providers. John Stephens joins Flowchem after decades of experience in industrial chemical research and development and manufacturing, including at Siege Engineering and PPG Industries (NYSE:PPG). These scientific leaders ensure that Flowchem remains at the forefront of DRA technology while maintaining its industry-leading quality and performance in reducing costs and emissions for customers across multiple product lines.
-
The Company has assembled a best-in-class Board of Directors of senior industry leaders with energy and chemicals experience:
- Cris Gaut (Chairman) – Chairman and former CEO, Forum Energy Technologies (NYSE:FET); former CFO, Halliburton (NYSE:HAL); former CFO and Co-President, Ensco International
- Joe Blount – former President and CEO, Colonial Pipeline; former CEO, Century Midstream LLC; former Chair of the Association of Oil Pipe Lines (AOPL)
- Scott Rogan – CFO, Eagle LNG Partners; former SVP, Targa Resources; former Partner and head of midstream investing, Energy Capital Partners
- Chris Oversby – former CEO, Optum Energy Solutions, a DRA technology business; former chemicals executive at Baker Hughes, Clariant & Univar
- Sean Rice – Managing Partner, SCF Partners
- Dan West – Managing Director, SCF Partners
- Cris Gaut (Chairman) – Chairman and former CEO, Forum Energy Technologies (NYSE:FET); former CFO, Halliburton (NYSE:HAL); former CFO and Co-President, Ensco International
Flowchem's CEO, Jon Blair, commented, “I am pleased to announce the appointment of Shivali Agarwal to COO. Shivali is a tremendous leader with a proven track record of success, and her operational expertise will enhance our efforts going forward. Our strengthened technology team and strategic board of directors will also be instrumental in improving our DRA solutions and enhancing the value we provide to our customers worldwide.”
Dan West, Managing Director at SCF Partners, stated, “Our team at Flowchem has demonstrated significant success in creating value for both customers and shareholders by making infrastructure operations safer, more efficient, and less emissions-intensive. We are excited to add these key leaders to reinforce and accelerate the company’s growth.”
About Flowchem, Val-Tex, and Sealweld
Flowchem is a leading supplier of Drag Reducing Agents (“DRA”) which optimize pipeline flow and increase throughput capacity. Use of Flowchem DRA enables infrastructure operators across the globe to reduce energy consumed in pumping operations, which in turn reduces both costs and associated greenhouse gas emissions and maximizes overall profitability of infrastructure operations. Flowchem provides flow consultation and turnkey solutions for pipeline applications worldwide. For more information, please visit www.flowchem-dra.com.
Val-Tex, founded in 1962, is one of the industry’s premier providers of high-quality valve maintenance products such as sealants, lubricants, fittings, and injection equipment. Val-Tex’s longstanding commitment to product excellence and customer satisfaction has earned the trust and recommendation of the world’s leading valve manufacturers. To learn more, please visit www.valtex.com.
Sealweld has provided superior valve care products and services since 1969, with a focus on the safe reduction and elimination of pipeline valve leakage. Decades of experience and development of practical solutions have resulted in high-performing valve care products equally suited to either gas or liquid pipelines. For more information, visit www.sealweld.com.
About SCF Partners
Founded in 1989, SCF provides equity capital and strategic growth assistance to build and grow leading energy service, equipment, and technology companies that operate throughout the world. SCF has invested in more than 80 platform companies and made more than 400 additional acquisitions to develop 18 publicly listed energy service and equipment companies over its history. The firm is headquartered in Houston, Texas, and has offices in Calgary, Aberdeen, and Australia. For more information, please visit www.scfpartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210052408/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom